This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The delivery of precise doses of THC via an inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions, according to clinicaltrialdata published in the European Journal of Pain.
Trauma patients administered oral THC consume fewer opioids than do similarly matched controls, according to clinicaltrialdata published in the journal Trauma Surgery & Acute Care. These opioid-sparing effects were most pronounced among participants who had prior experience with cannabis.
The administration of oral CBD reduces cue-induced cravings and anxiety in subjects with a history of heroin use, according to clinicaldata published in The American Journal of Psychiatry. ” In observational models , patients with legal access to cannabis typically reduce or eliminate their use of opioids.
About nine months earlier, another review by a team of Thai researchers appeared in the journal Cannabis and Cannabinoid Research. Ultimately, they concluded that the available data on pain and other outcomes was unreliable, with a high risk of bias. New clinicaltrials are urgently needed, they repeat in a familiar refrain.
The call for comments, posted on April 17 at regulations.gov here , states: “Interested persons or organizations are invited to participate by submitting written views, recommendations, and data related to perspectives on and experiences with pain and pain management. percent in 2016).”
There is an absence of clinicaldata supporting the efficacy of CBD as an antiviral agent, according to a systematic literature review published in the journal Cannabis and Cannabinoid Research. However, this data was based solely on preclinical findings. ” — appears online here.
Research and anecdotal reports have already displayed that cannabis can be used to treat the symptoms of migraines. However, there has not been a clinicaltrial assessing the efficacy of cannabis for migraines, at least not until now. The First ClinicalTrial for Migraines and Cannabis.
Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. As two emergent complementary medicines, many parallels exist between the medical cannabis industry and the currently developing psychedelic medicine industry.
Seventy-five percent of military veterans say that they would consider using either “cannabis or cannabinoid products as a treatment option,” according to member survey data compiled by the group Iraq and Afghanistan Veterans of America (IAVA). The organization represents over 400,000 veterans nationwide.
MoreBetter, creators of the Releaf App, is using this real world data to push back against the claim that there’s no evidence that CBN can help people sleep. In September 2021, MoreBetter hosted a self-reported data collection with this CBN tincture offered to participants for free of charge from CBDistillery. Here’s what they found.
Just about any industry benefits greatly from the proper use and evaluation of data. The tech giants of today are built mostly on data regarding their users, and advertisers rely on that data to more effectively target their efforts. How to Use the Data. Men were more likely than women to treat pain with cannabis.
The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. billion, servicing nearly 340,000 active patients. RYAH Group, Inc.
We look forward to his expertise as we expand our mental health analytical platform and enter clinicaltrials. Our main product is the Ehave Dashboard which is a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insight using Blockchain technology. Ehave, Inc.
IGC”) (NYSE American: IGC) announces today that it has completed Cohort 2 of its Phase 1 clinicaltrial on IGC’s tetrahydrocannabinol (“THC”)-based investigational new drug, IGC-AD1, intended to alleviate the symptoms of individuals suffering from Alzheimer’s disease. This Phase 1 trial is currently testing IGC-AD1 for safety.
InMed and CHDR are currently preparing the ClinicalTrial Application for a second Phase 1 clinicaltrial (755-102-HV), planned to begin in the second quarter of 2020, which will examine the local safety of INM-755 on small areas of wounded skin in healthy volunteers.
“Securing ClinicalTrial Authorisation solidifies over 16 months of hard work and dedication from our team and positions Halucenex as one of very few Canadian companies with approval to commence a clinicaltrial utilising psychedelic substances on mental health conditions,” president, CEO and founder Bill Fleming said.
If you thought there was no relationship between cannabis use and technology, consider these stats: the average number of mobile apps being used in a day by current cannabis users are 4. Virtual ClinicalTrials transcend geographic, mobility and economic barriers. Authored By : Arundati Dandapani.
Nasdaq: AIKI ) (“AIkido” or the “Company”) today announced that positive Phase 1 testing data was presented at the 2021 ASCO Annual Meeting June 4 , 2021. Clinicaltrial information: NCT03276572 ( [link] ). NEW YORK , June 4, 2021 /PRNewswire/ — AIkido Pharma Inc. Abstract Number: 5015.
Researchers studying the efficacy of marijuana treatments for veterans’ mental health now have access to $20 million in marijuana tax revenue to fund clinicaltrials. Department of Veteran Affairs’ most recent data. None of it was initially slated to go to clinicaltrials. Between Dec. Read more at.
His first initiative is co-authoring an original study on epilepsy using survey data gathered from RoC’s innovative Observational Research Registry (ORR). Schlienz, a clinical psychologist, led the development of the ORR as a postdoctoral research fellow at Johns Hopkins University. About Realm of Caring.
But there’s another option that can address mood, pain, and more at once, all with fewer side effects: cannabis. Nor is it necessarily surprising, given the ability of cannabis to target the ubiquitous, homeostasis-seeking endocannabinoid system. It’s not a new idea.
A new study shows that the inhalation of cannabis could be linked to improvements and better quality of life for those with ulcerative colitis. The study was carried out by researchers in Israel, who looked at how inhaling herbal cannabis impacted ulcerative colitis patients over a period of eight weeks, with continued, steady, use.
Clinicaltrials into cannabis’ potential as an opioid replacement are well underway in South Africa. ” Dr. Gallow prides himself on his work as a South African cannabis advocate and leader in the international medical cannabis research field. It has been fairly slow,” explained Dr. Gallow.
New data shows MYMD-1 has key differentiators and capabilities compared to existing TNF inhibitor drugs. Company plans to initiate Phase II trial with a leading academic institution. These advanced analytics provide a human-centric, data-driven approach to phenotypic discovery for clients.”.
This article was originally published on Analytical Cannabis and appears here with permission. . In a new survey of German patients with Parkinson’s disease, 8% of patients reported using cannabis products. Of these consumers, over half said the drug had a beneficial clinical effect on their condition.
(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinicaltrial for IGC-AD1. The results of the clinicaltrial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.
The Financing will allow the Company to continue progressing its R&D, clinicaltrials and technology initiatives. “I I’m proud of our accomplishments to date and look forward to kicking off multiple clinicaltrials in early 2022,” said CEO, Josh Bartch. DENVER, Dec. Advancements in IP and Drug Development.
This commentary on the NICE UK cannabis guidelines is originally published by The Academy of Medical Cannabis , the globally leading institute for clinical training and research in cannabis-based medicinal products. Since the early 1990s, Israel has stood at the front line of cannabis medicalization.
Gaize is mastering the art of cannabis impairment detection. The Missoula, Montana-based company is gearing up for the launch of its first science-backed real-time cannabis impairment detection device. Studies on cannabis have shown that the plant may cause disorientation, sedation, lack of concentration, and impaired judgment.
THE UK’s first National Health Service patients registry will start collating data from Thursday this week in a significant move for medical cannabis in the country. The development has been welcomed and comes as the nation’s doctors are said to be shifting their cultural stance from viewing ‘cannabis as a dirty word’.
ClinicalTrials and Reporting The bill breaks new ground by allowing clinicaltrials to take place regardless of whether the tested substances fall under federal or military statutes. This will ensure that lawmakers stay informed about the program’s developments and can respond accordingly as new data emerges.
Like many people who are drawn to work with and advocate for medical cannabis , I first saw the difference that cannabis can make with someone very close to me. The more I read about it, the more I became fascinated with the chemistry and potential of cannabis. Transfering nurses’ skills to cannabis medicine.
The CBD she took may or may not have helped, but according to a recent survey of tinnitus patients, she wasn’t alone in trying — or at least in being interested in cannabis as a potential remedy. Among the 45 respondents, median age 55, only 10 said they were current cannabis users (19 had never used, and 16 had used in the past).
A study investigated psilocybin’s effect on alcohol addiction, the FDA outlined best practices for future psychedelic research, and the NCAA is inching toward cannabis policy change. For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinicaltrial.
This article was first published on Analytical Cannabis. And when these data were included, the researchers found a significant overlap in the reports from participants who thought they had taken the drugs, even when they hadn’t. It appears here with permission.
A fascinating new clinicaltrial demonstrates how this psychedelic compound could make people significantly more comfortable while undergoing MRIs or similar procedures. All imaging and behavioral data will be accessible to the public after the study is complete. What Is an MRI?
Psymposia report… O n Sep 23, 2021, Psymposia staff received an email from the personal email account of Mark Haden — the former Executive Director of psychedelic nonprofit MAPS Canada and current Director of ClinicalTrials for Psygen Inc. MAPS Canada’s Data Breach Foreshadows Corporadelic Future.
There’s no doubt that the amount of information that is available about cannabis is at an all-time high – in 2020 alone, over 3,500 scientific articles were published on the topic. Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. The cannabis problem.
The Canadian weed giant marked a milestone in Germany this week, harvesting the country’s first medical cannabis crop. Tilray is embarking on a push to educate more German doctors about the benefits of prescribing medical cannabis, as the weed giant seeks to cement its dominance in the highly-profitable European medical market.
InMed and CHDR are currently preparing the ClinicalTrial Application for a second Phase 1 clinicaltrial (755-102-HV), planned to begin in the second quarter of 2020, which will examine the local safety of INM-755 on small areas of wounded skin in healthy volunteers.
Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. Guy Goodwin appointed Chief Medical Officer and Danielle Schlosser appointed Senior Vice-President, Clinical Innovation. On track to report top-line data by end of 2021.
Flora Pharma will seek to identify scientific gaps in the cannabis industry and ultimately work to translate that to pharmaceutical cannabis products backed by data. Flora Pharma expects to fast track traditional FDA and NHS timelines by running phase trials in parallel (in vitro, in vivo, pilot in human, safety/efficacy, etc.).
With new and improved products popping up left and right, legalization initiatives taking off all over the globe, and harmful “stoner” stigmas quickly dissipating, it’s clear that cannabis has entered a new era. The days of “reefer madness” are long over, replaced by a growing acknowledgment of the cannabis plant’s therapeutic abilities.
Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for the clinicaltrial evaluating Nantheia™ ATL5, an investigational drug using cannabidiol (CBD) in ANANDA’s proprietary delivery technology as an Adjunctive Treatment for Opioid Use Disorder. Clinical Trials.gov Identifier: NCT03787628 ).
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content